Bottom line
Is SHPCX a good fund? The bottom line
SHPCX is the Health & Biotechnology Porfolio Class C share class of Health & Biotechnology Portfolio, a managed technology sector mutual fund from Saratoga Advantage.
Annual fees run 3.6% — about $360 a year on every $10,000 invested, more expensive than 100% of technology sector funds we track.
It returned −1.3% over one year, +3.7% a year over five years, +4.1% a year over ten (as of Dec 31, 2024, per its prospectus).
With $10.5 million in net assets and 29 holdings, its largest position is Cardinal Health Inc (6.4%) and the top 10 make up 50.7% of the portfolio.
What stands out
- No front-end sales load
What to watch
- Expensive for its category (3.6%)
- Concentrated: top 10 holdings are 50.7% of assets
- Small fund ($10.5 million) — small funds are likelier to close
Updated Nov 19, 2026
What SHPCX invests in
The Health & Biotechnology Portfolio seeks long-term capital growth.
The Portfolio will normally invest at least 80% of its total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value (or market capitalization). Equity securities include common stocks, preferred stocks, securities convertible into common stocks and warrants. The Adviser utilizes a top-down investment approach focused on long-term economic trends. The Adviser begins with the overall outlook for the economy, then seeks to identify specific industries with attractive characteristics and long-term growth potential. Ultimately, the Adviser seeks to identify high-quality companies within the selected industries and to acquire them at attractive prices. The Advisers stock selection process is based on an analysis of individual companies fundamental values, such as earnings growth potential and the quality of…
From the fund's prospectus (filed Dec 29, 2025).
SHPCX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| SHPCX | −1.3% | +3.7% | +4.1% |
| Technology Sector median | +24.0% | +10.0% | +16.7% |
Source: Fund prospectus, as of Dec 31, 2024
What SHPCX costs
On a $10,000 investment, SHPCX's 3.6% expense ratio costs about $360 a year. The prospectus estimates $3,862 in total costs over 10 years (assuming 5% annual returns). The median technology sector fund charges 0.75%.
SHPCX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Cardinal Health Inc | 6.44% |
| 2 | Jazz Pharmaceuticals Plc | 6.19% |
| 3 | United Therapeutics Corp | 6.17% |
| 4 | Amgen Inc | 5.04% |
| 5 | Mckesson Corp | 4.90% |
| 6 | Lantheus Holdings Inc | 4.64% |
| 7 | Exelixis Inc | 4.55% |
| 8 | Novartis Ag | 4.50% |
| 9 | Cencora Inc | 4.33% |
| 10 | Gilead Sciences Inc | 3.94% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 50.7% of the fund. See all top 25 holdings and asset mix →